Inactief instrument

Andere talen Atossa Genetics Inc Nasdaq

Aandelen

US04962H2094

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	15/05
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial	15/05
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	15/05
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering	13/05
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	13/05
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines	07/05
Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force	07/05
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen	29/04
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	29/04
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer	16/04
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	15/04
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	15/04
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	11/04
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04
North American Morning Briefing : Stocks Seen -2-	02/04
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	01/04
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient	20/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Atossa Genetics Inc Nasdaq

Aandelen

US04962H2094

Andere talen

Filters